Atomic Oncology: Research update
Our research update on Atomic Oncology goes into detail on strategic and clinical updates since the last report in September this year.
Since we first wrote about Atomic Oncology earlier this year, the business has been busy refining its clinical development and commercialisation strategies to accelerate and broaden its initial clinical validation studies in lymphoma, prostate cancer and glioblastoma, and to position the business to be able to commercialise its Radnos test in the US market.
Our research note goes into detail on these developments and explores the significant impact they will have on the speed and scale of the commercialisation of the Radnos test.
As a reminder, Atomic Oncology has developed a unique, patented diagnostic technology that determines where any solid cancer in any patient sits on the radio responsiveness spectrum. This score will provide oncologists with the knowledge to predict whether radiotherapy will be successful for any solid cancer. The benefits for patients are clear, but so are they for payers, who, using this technology, can avoid harmful and wasteful expenditure on radiotherapy that, in some cases, will be of no benefit to the patient.
Important information
The views expressed in this article are those of the author at the date of publication and not necessarily those of Curated Capital Ltd. The contents of this article are not intended as investment advice and will not be updated after publication unless otherwise stated.